Connect with us
Information

WORLD EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

WORLD EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

Biotech Market
Biotech News
Biotech Stocks

Amplia Therapeutics Limited

ASX:ATX

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Featured Articles and Interviews

More Featured Articles and Inverviews

Press Releases

Oct 29, 2024

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Sep 22, 2024

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

Sep 19, 2024

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

More Press Releases

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Go Deeper

AI Powered

Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks of 2025

Microscopic view of stem cells.

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.